- No need to diet: Reducing protein intake can fight obesity
- Eisai/Bogen second Alzheimer’s drug has positive Phase 3 clinical results
- Why does Ebola virus become the ‘Replication Machine’?
- FDA Approved a Neurostimulation Therapy for Major Depressive Disorder
- What is the research progress of immunotherapy for Alzheimer’s disease?
- Protein linked to significantly increased risk of Alzheimer’s disease
Burden of arrhythmia in patients with multiple myeloma and clinical impacts
Burden of arrhythmia in patients with multiple myeloma and clinical impacts. Identifying MM patients at high risk of arrhythmia can more proactively reduce cardiovascular risk, thereby reducing mortality, medical costs and patient hospital stays.
Arrhythmia often occurs in patients with multiple myeloma (MM). A variety of causes can cause arrhythmia, such as age, cardiotoxicity of chemotherapy drugs, cardiac amyloidosis and electrolyte disturbances.
The purpose of this study is to evaluate the arrhythmia burden of MM patients and its impact on clinical outcomes compared with the normal population.
The researchers used the US hospitalized patient database from September 2015 to December 2017 and used the ICD 10 CM coding system to identify whether the patient had MM, and to further identify the population with arrhythmia in the two groups. Then, the patient’s baseline characteristics and Elixhauser comorbidity were matched with propensity scores to evaluate the outcome of MM patients with or without arrhythmia.
The data of 68,095,278 patients were collected from American hospitals for evaluation, and they were divided into MM and non-MM patient groups.
Compared with non-MM patients, the average age of MM patients was older. Compared with non-MM patients, MM patients have a higher incidence of complications, such as congestive heart failure (15.6% vs 9.5%), hypertension (56.6% vs 47.6%), and electrolyte imbalance (40% vs 23.7%) And arrhythmias, including atrial fibrillation (8.7% vs 5.9%) and atrial flutter (2.1% vs 1.3%).
This study compared MM patients with and without arrhythmia, and found that MM patients with arrhythmia had a higher incidence of congestive heart failure, and higher in-hospital mortality and hospital costs (9.2% vs 4.1% and $12,984, respectively vs $11,028).
Identifying MM patients at high risk of arrhythmia can more actively reduce cardiovascular risk, thereby reducing mortality, medical costs and patient hospitalization. Baseline assessment of heart function, adjustment of the dose of cardiotoxic chemotherapy drugs, reasonable management of electrolyte disturbances, screening for cardiac amyloidosis, and early assistance between cardiologists and oncologists can benefit these patients
(source:internet, reference only)